tbuckley/cabot-search huggingface dataset:
Lower Placental Leptin Promoter Methylation in Association with Fine Particulate Matter Air Pollution during Pregnancy and Placental Nitrosative Stress at Birth in the ENVIR <i>ON</i> AGE Cohort
Authors: Nelly D. Saenen, Karen Vrijens, Bram G. Janssen, Harry A. Roels, Kristof Y. Neven, Wim Vanden Berghe, Wilfried Gyselaers, Charlotte Vanpoucke, Wouter Lefebvre, Patrick De Boever, Tim S. Nawrot
Journal: Environmental Health Perspectives (2016)

Particulate matter with a diameter ≤ 2.5 μm (PM2.5) affects human fetal development during pregnancy. Oxidative stress is a putative mechanism by which PM2.5 may exert its effects. Leptin (LEP) is an energy-regulating hormone involved in fetal growth and development.We investigated in placental tissue whether DNA methylation of the LEP promoter is associated with PM2.5 and whether the oxidative/nitrosative stress biomarker 3-nitrotyrosine (3-NTp) is involved.LEP DNA methylation status of 361 placentas from the ENVIRONAGE birth cohort was assessed using bisulfite-PCR-pyrosequencing. Placental 3-NTp (n = 313) was determined with an ELISA assay. Daily PM2.5 exposure levels were estimated for each mother's residence, accounting for residential mobility during pregnancy, using a spatiotemporal interpolation model.After adjustment for a priori chosen covariates, placental LEP methylation was 1.4% lower (95% CI: -2.7, -0.19%) in association with an interquartile range increment (7.5 μg/m3) in second-trimester PM2.5 exposure and 0.43% lower (95% CI: -0.85, -0.02%) in association with a doubling of placental 3-NTp content.LEP methylation status in the placenta was negatively associated with PM2.5 exposure during the second trimester, and with placental 3-NTp, a marker of oxidative/nitrosative stress. Additional research is needed to confirm our findings and to assess whether oxidative/nitrosative stress might contribute to associations between PM2.5 and placental epigenetic events. Potential consequences for health during the neonatal period and later in life warrant further exploration. Citation: Saenen ND, Vrijens K, Janssen BG, Roels HA, Neven KY, Vanden Berghe W, Gyselaers W, Vanpoucke C, Lefebvre W, De Boever P, Nawrot TS. 2017. Lower placental leptin promoter methylation in association with fine particulate matter air pollution during pregnancy and placental nitrosative stress at birth in the ENVIRONAGE cohort. Environ Health Perspect 125:262-268; http://dx.doi.org/10.1289/EHP38.
P2-243: A Phase II study of Carboplatin plus Pemetrexed in previously treated patients with non-small cell lung cancer (NSCLC)
Authors: Andriani G. Charpidou, Antonis Zalonis, Evgenia Katirtzoglou, Sofia Stamatopoulou, Evangelia Chondrou, Anastasios Boufas, Aggeliki Rapti, Kostas N. Syrigos
Journal: Journal of Thoracic Oncology (2007)
P1-125: Aberrant methylation of DAP-K, p-16, MGMT, RAR-β and HPP1 in thymic epithelial tumor
Authors: Yukiko Hirose, Kazuya Kondo, Taeko Nagao, Hiroaki Toba, Takanori Miyoshi, Syouji Sakiyama, Akira Tangoku
Journal: Journal of Thoracic Oncology (2007)
PD2-2-4: Bronchiolar columnar cell dysplasia in the lungs resected due to primary non small cell cancer -preliminary report
Authors: Walentyn Pankiewicz, Jerzy Laudanski, Wojciech Naumnik, Wieslawa Niklinska, Jacek Niklinski, Lech Chyczewski
Journal: Journal of Thoracic Oncology (2007)
P2-230: A Phase I Study of Nontoxic Suramin As A Chemosensitizer In Pretreated/Refractory Non-Small Cell Lung Cancer (NSCLC) Patients
Authors: J.L.S. Au, T Olencki, M.G. Wientjes, G Otterson, T Saab, A Grainger, T Yeh, R Jensen, D Young, M villalona Calero
Journal: Journal of Thoracic Oncology (2007)
Long‐Term Subconjunctival Delivery of Brimonidine Tartrate for Glaucoma Treatment Using a Microspheres/Carrier System
Authors: Y. Shona Pek, Hong Wu, Siti Thaharah Mohamed, Jackie Y. Ying
Journal: Advanced Healthcare Materials (2016)

Core‐shell polymer microspheres with poly( d,l ‐lactic‐co‐glycolic acid) core and poly( l ‐lactic acid) (PLLA) shell are developed for the long‐term subconjunctival release of brimonidine tartrate (BT) in order to reduce intraocular pressure (IOP) in the treatment of glaucoma. The PLLA‐rich shell acts as a diffusion barrier, enabling linear release of BT over an extended period of 40 d. The microspheres are encased in a porous non‐degradable methacrylate‐based carrier for ease of subconjunctival implantation in a glaucoma‐induced rabbit model. In vivo release of BT from the microspheres/carrier system has enabled a significant, immediate IOP reduction of 20 mmHg, which is sustained for 55 d. Long‐term IOP reduction may be maintained by periodic replacement of the microspheres/carrier system.
P3-150: Phase II study of erlotinib in patients with advanced non-small cell lung cancer who failed prior gefitinib treatment
Authors: Yu-Ning Shih, Jia-Ling Liou, Wan-Chian Jiang, Kao-Ting Chang, Chao-Hua Chiu, Chun-Ming Tsai
Journal: Journal of Thoracic Oncology (2007)
Differential Influence of Lung Cancer Stage, Time from Diagnosis and Chemotherapy on Plasma and Cellular Biomarkers of Hypercoagulability. the Roadmap Study
Authors: Ilias Evmorfiadis, Paraskevi Boura, Aurélie Rousseau, Ariadni Charpidou, Giannis Giozos, Patrick Van Dreden, Konstantinos Syrigos, Anastasia Spanoudaki, Matthieu Grusse, Ismail Elalamy, Grigorios T. Gerotziafas
Journal: Blood (2014)
P0824 : A phase 1 study to evaluate the interaction of HCV NS5B inhibitor MK-3682 with HCV NS3/4A protease inhibitor MK-5172 And HCV NS5A inhibitor MK-8408 in healthy subjects
Authors: X.-J. Zhou, E. Sicard, J. Chen, D. Frank, W. Gao, M.L. Rizk, E.G. Rhee, J.R. Butterton, J. Sullivan-Bolyai
Journal: Journal of Hepatology (2015)
Epigenomic Profiling of Multiple Myeloma Shows Widespread Stage Specific Alterations In DNA Methylation That Occur Early During Myelomagenesis
Authors: Christoph Heuck, Jayesh Mehta, Joseph Tariman, Natalie Pulliam, Yiting Yu, Tushar Bhagat, Sangeeta Nischal, Richard Meagher, Caroline Y. Hu, Amit Verma, Seema B. Singhal
Journal: Blood (2010)
Canada’s ban on private healthcare faces legal challenge
Authors: Owen Dyer
Journal: BMJ (2016)

Canadian laws banning private healthcare for serious medical conditions are facing their first notable legal challenge in decades, in a case spearheaded by a former president of the Canadian Medical Association.

The case before the Supreme Court of British Columbia has pitted Cambie Surgical Centre of Vancouver and five patients against the province’s Medical Services Commission. But its ramifications for healthcare across Canada led the federal government to request standing as an intervenor in the case.

Health Canada argued that the provincial legislation being challenged has language that mirrored the Canada Health Act, “making this case of significant importance not only to British Columbians, but to all Canadians.”

Noting that Canadians “overwhelmingly” supported universally accessible healthcare, the federal department argued that “any challenge to a principle …
Of Insects and Hereditary Disease—The Contributions of Edward Cockayne
Authors: Parth Patel, Arpan V. Prabhu, Melissa Pugliano-Mauro
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Clarifying misunderstandings and misinterpretations about proton pump inhibitor-responsive oesophageal eosinophilia
Authors: Javier Molina-Infante, Ikuo Hirano, Stuart J Spechler
Journal: Gut (2016)

We appreciate the interest of Muir et al 1 in our Position Paper on proton pump inhibitor-responsive oesophageal eosinophilia (PPI-REE).2 Their letter highlights the ongoing controversies related to PPI-REE, particularly regarding practical diagnostic concerns in paediatric patients. We would like to address several issues raised by the authors: 

1.  When the clinical presentation is consistent with gastro-oesophageal reflux disease (GORD), an empiric trial of PPI therapy is always appropriate. Teenagers and adults with dysphagia, however, should undergo an endoscopic procedure, because dysphagia is a red-flag symptom. In adult patients with dysphagia and suspected eosinophilic oesophagitis (EoE), a baseline endoscopy off PPI therapy has diagnostic value. This approach has not led to unnecessary endoscopies or diagnostic confusion, as suggested by Muir et al .1 Instead, it has elucidated the existence and improved our understanding of PPI-REE in adult patients.2 The different and more non-specific clinical presentation of …
Autologous Stem Cell Transplantation (ASCT) for AIDS-Related Lymphomas (ARL) and the Potential Role of HIV-Resistant Stem Cells.
Authors: Amrita Y. Krishnan, John A. Zaia, John J. Rossi, Arturo Molina, Mingjie Li, Wendy Lee, Ramesh Akkina, Nicole Tsai, Shirley Li, Priscilla Yam, Haitang Li, Jiing-Kuan Yee, David Hsu, Larry Couture, David DiGiusto, Stephen J. Forman
Journal: Blood (2006)
Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management
Authors: Francis X. McCormack, Nishant Gupta, Geraldine R. Finlay, Lisa R. Young, Angelo M. Taveira-DaSilva, Connie G. Glasgow, Wendy K. Steagall, Simon R. Johnson, Steven A. Sahn, Jay H. Ryu, Charlie Strange, Kuniaki Seyama, Eugene J. Sullivan, Robert M. Kotloff, Gregory P. Downey, Jeffrey T. Chapman, MeiLan K. Han, Jeanine M. D’Armiento, Yoshikazu Inoue, Elizabeth P. Henske, John J. Bissler, Thomas V. Colby, Brent W. Kinder, Kathryn A. Wikenheiser-Brokamp, Kevin K. Brown, Jean F. Cordier, Cristopher Meyer, Vincent Cottin, Jan L. Brozek, Karen Smith, Kevin C. Wilson, Joel Moss
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

Section:ChooseTop of pageAbstract <<ContentsOverviewIntroductionMethodsQuestion 1: Should Patien...Question 2: Should Patien...Question 3: Should Patien...Question 4: Should VEGF-D...ConclusionsFuture DirectionsReferencesCITING ARTICLES
Comparison of Tissue Elastography With Magnetic Resonance Imaging T2* and Serum Ferritin Quantification in Detecting Liver Iron Overload in Patients With Thalassemia Major
Authors: Nirav Pipaliya, Dattatray Solanke, Pathik Parikh, Meghraj Ingle, Ratna Sharma, Sujata Sharma, Prabha Sawant
Journal: Clinical Gastroenterology and Hepatology (2016)
Novel strategy to identify drugs that delay relapse.
Authors: M. Hall, J. Evans, D. E. Kornbrot, M. Persic, S. Tahir, J. Morgan, C. Gourley, N. S. Stuart, S. M. Crawford, G. J. Rustin
Journal: Journal of Clinical Oncology (2010)

3075 Background: There is an urgent need for methods to screen novel agents capable of stabilizing advanced cancer, prior to undertaking large randomized trials. This study was set up to determine whether, in asymptomatic relapsed ovarian cancer patients, their rising CA125 levels could be used to test the activity of such novel drugs. For proof of principle, tamoxifen is used. Methods: Patients with ovarian cancer who had responded to relapse chemotherapy were registered and had regular CA125 measurements: tamoxifen was started when CA125 reached × 4 nadir or × 4 ULN. Slopes of the regression of lne (CA125) against time for the last three values before starting tamoxifen and the first three levels after starting tamoxifen were compared for each patient. A repeated measures t-test was conducted to determine the magnitude and statistical significance of the difference between the mean slope before starting tamoxifen and during tamoxifen treatment. Results: To date 73 of 172 (42%) of subjects had 3 CA125 levels before and after starting tamoxifen and so were considered evaluable. 25% of registered patients were evaluable within 20 weeks of trial registration and consequently completed the trial within 6 months. The change in regression slope comparing before tamoxifen and during tamoxifen was highly significant, effect size (Cohen's d) = 0.69 (p = 0.0000001). Hence 25 evaluable (∼100 registered) patients would have an estimated power of .9 to detect a change in slope. The CA125 doubling time increased from 30 days prior to tamoxifen to 57 days. Conclusions: This trial has shown that if a novel cytostatic drug is as effective as tamoxifen, fewer than 100 patients need to be entered on study, for a period of 6 months, in order to have a 90% power to show a significant change in CA125 doubling time. This trial design is therefore an ideal method for selecting agents to take through to large, expensive randomized trials. No significant financial relationships to disclose.
P1238 : Intermediate familial intrahepatic cholestasis (IFIC): Phenotypic spectrum within the BRIC-PFIC spectrum
Authors: I. Giovannoni, F. Callea, E. Bellacchio, G. Torre, V. Nobili, J. De Ville De Goyet, G. Maggiore, R. Boldrini, P. Francalanci
Journal: Journal of Hepatology (2015)
“Regards Croisés 2009”: French survey about perception and management of fatigue-related cancer.
Authors: C. Chouaid, P. Colin, F. Maloisel, E. Mitry, P. Le Calve, L. H. Zelek
Journal: Journal of Clinical Oncology (2010)

e19653 Background: Despite the frequency of fatigue related-anemia in patients, and its repercussions on the quality of life, patient management remains inadequate. Moreover, few data are available concerning the opinion and feeling of both patients and health professionals on this very frequent symptom in cancer-treated patients. This survey was conducted to asses the position and perception of fatigue in patients treated with chemotherapy, as well as the perception of physicians and nurses who care for these patients. Methods: This quantitative survey of 300 patients, 250 physicians (oncologists, hematologists, pneumologists, and gastroenterologists) and 109 nurses was conducted in public and private French centers. The questionnaires and setup were performed by an independent market research agency under the validation of a multidisciplinary group of experts. Patients included had a diagnosis of breast, lung or colorectal cancer, or non-myeloid malignant hemopathy, were undergoing ambulatory chemotherapy, and presented or had presented with anemia (Hb <11 g/dL) during chemotherapy. The mean hemoglobin (Hb) level at the start of treatment was 9.3±0.86 g/dL and the ongoing mean Hb rate was 10.44±1.09 g/dL. 64% of patients were treated for anemia (transfusion and\or erythropoiesis-stimulating agents). Results: Fatigue was the most common symptom reported for 77% of the patients. In 37% of these cases, fatigue was described as the main problem affecting daily life. Fatigue was evaluated as intense. Most health professionals agreed with the patient's experience. The three surveyed populations agreed that the causes of fatigue were due to multiple factors; however, for the patients, fatigue was less frequently related to anemia. Patients appeared globally satisfied with management and treatment of their cancer but less satisfied with the treatment of their fatigue. The three surveyed populations were in agreement with the importance of good management of this symptom. Conclusions: This survey objectified the need of good management of fatigue in cancer patients confirmed by the different perceptions from patients and health professionals. No significant financial relationships to disclose.
Urinary frequency and dysuria in an older woman
Authors: Joseph Dalby Sinnott, David C Howlett
Journal: BMJ (2016)

A 66 year old woman with diabetes was admitted to the medical assessment unit with lower abdominal pain and dysuria. The patient was pyrexial (38.8°C) and had a white cell count of 17.1×109/L. A urine dipstick test was positive for leucocytes, nitrites, and blood. Computed tomography (fig 1⇓) was performed because of the severity of the lower abdominal pain. What is …
P3-133: Bortezomib for advanced Bronchioloalveolar Carcinoma (BAC): a California–Pittsburgh Cancer Consortium multicenter phase II study
Authors: Suresh S. Ramalingam, Angela M. Davies, Jeff Longmate, Everett E. Vokes, John Wright, David R. Gandara, Chandra P. Belani
Journal: Journal of Thoracic Oncology (2007)
P3-208: Clinical features and treatment outcome of bronchioloalveolar carcinoma defined by who classification
Authors: Tae Kyu Lim, Jin Seok Ahn, Jeeyun Lee, Myung-Ju Ahn, Jung Ho Han, Kyung Soo Lee, Jhingook Kim, Young Mog Shim, Hojoong Kim, Keunchil Park
Journal: Journal of Thoracic Oncology (2007)
Intraventricular Hemorrhage in the Premature Infant
Authors: Shlomo Shinnar, Richard A. Molteni, Karen Gammon, Bernard J. D'Souza, Jeremy Altman, John M. Freeman
Journal: New England Journal of Medicine (1982)

OVER the past decade morbidity and mortality among very-low-birth-weight preterm infants decreased dramatically. With improved survival, a previously rare diagnosis — intraventricular hemorrhage — became increasingly common.1 Introduction of the CT scanner revealed that 32 to 44 per cent of infants weighing under 1500 g at birth had subependymal hemorrhage or intraventricular hemorrhage. Routine scanning of infants weighing under 1800 g became common. The mortality from severe hemorrhage was estimated to be 50 to 65 per cent, and hydrocephalus was believed to develop in 45 to 100 per cent of the survivors.2 3 4 5 6 7 Various medical approaches to the therapy of posthemorrhagic . . .
P1179 : Connecting the liver and gut in PSC: Intestinal CCL25 is increased in colitis, correlates with inflammatory activity and facilitates effector CCR9+ lymphocyte recruitment
Authors: P.J. Trivedi, T. Bruns, S.T. Ward, E. Liaskou, M. Mai, C. Schmidt, G.M. Hirschfield, C.J. Weston, D.H. Adams
Journal: Journal of Hepatology (2015)
Cerebral Small Vessel Disease In Patients With Sickle Cell Disease: Initial Findings With Ultra-High Field 7T MRI
Authors: Veronica van der Land, Jaco J.M. Zwanenburg, Bart J Biemond, Jeroen Hendrikse, Henk-Jan Mutsaerts, Marc Engelen, Aart J. Nederveen, Charles B.L.M. Majoie, Peter R. Luijten, Karin Fijnvandraat, Paul J. Nederkoorn
Journal: Blood (2013)
NHS is not in “land of milk and honey” with tough choices ahead, warns head of NHS
Authors: Adrian O’Dowd
Journal: BMJ (2016)

The NHS faces tough choices over what services it can continue to provide and controversies about the reality of funding available to it, the head of the NHS in England has said.

Simon Stevens, chief executive of NHS England, appearing before the Parliamentary Public Accounts Committee on 14 September to discuss NHS finances, gave a frank assessment of some tough years ahead for the NHS despite the government’s often cited additional £10bn (€12bn; $13bn) funding for the service up to 2020.

MPs said that the Department of Health’s accounts1 showed that the NHS was on a “very sticky wicket” in achieving the goals of the Five Year Forward View2 to modernise and improve the NHS.

Stevens said, “The accounts do show we …
Prognostic significance of blood counts at time of complete remission in acute myeloid leukemia
Authors: M. Yanada, G. Borthakur, G. Garcia-Manero, F. Ravandi, S. Faderl, S. Pierce, H. M. Kantarjian, E. Estey
Journal: Journal of Clinical Oncology (2008)

7078 Background: Prediction of relapse-free survival (RFS) in acute myeloid leukemia (AML) has focused on use of pre-treatment variables, e.g. cytogenetics, or indicators of minimal residual disease once in complete remission (CR), e.g. aberrant immunphenotypes or PCR. Here we examine whether a much simpler test, namely the complete blood count at time of CR, might also predict RFS. Methods: Adults treated for AML (≥20% blasts, acute promyelocytic leukemia excepted) at M. D. Anderson from 1991 to 2003 were included for analysis if they achieved CR with 1 course of cytarabine-containing induction therapy. We first randomly divided such 891 patients into 2 groups of 446 and 445 patients, and established optimal cutoffs for neutrophil and platelet counts and hemoglobin level in the first 446 patient “training set”. Then we tested whether these cutoffs were, after accounting for better known prognostic covariates, also predictive of RFS in the 445 patient “validation set”. Results: In the training set, patients with higher blood counts at CR had significantly better RFS. For neutrophil and platelet counts, the 75th percentiles gave the lowest p-value (log-rank p<0.01 for both), while for hemoglobin the 25th percentile produced the optimal cutoff (log-rank p=0.02). In the validation set, the Cox model indicated significant relationship between higher neutrophil and platelet counts at CR which were defined according to these cutoffs, and superior RFS after accounting for the other covariates including time to CR (hazard ratio [HR] 1.38, 95% confidence interval [CI] 1.05–1.83, p=0.02 for neutrophils; HR 1.35, 95% CI 1.01–1.80, p=0.04 for platelets). Findings were analogous if only patients treated on protocols not calling for G-CSF administration were considered. Conclusions: These results suggest that blood counts at time of CR provide additional independent prognostic information in AML. Given the simplicity, availability, and inexpensive nature of the test, further exploration of blood counts at CR as a potential predictor of RFS is warranted. No significant financial relationships to disclose.